Knee injury often misdiagnosed on MRI is common in competitive alpine skiers, other high-level athletes

Many young competitive alpine skiers have bony lesions near their knees that are often thought to be more serious conditions such as cancer. These MRI findings, however, are not dangerous and may be prevalent in a number of high-level athletes.

That’s what a team of Swiss researchers found after comparing knee MRIs of 105 young alpine skiers to an equal amount of control patients. These distal femoral cortical irregularities, as they’re known, affect a thigh bone close to the knee and may resemble a tumor.

But lead author Christoph Stern, MD, a musculoskeletal radiologist at Balgrist University Hospital in Zürich, warns that radiologists should be careful not to misdiagnose such injuries.

“DFCI are benign lesions, and occurrence around the knee joint is associated with repetitive mechanical stress to the attachment sites of tendons into bone,” Stern said in a statement. “DFCI should not be mistaken for malignancy and are not associated with intraarticular damage.”

Looking at MRIs collected between 2014 and 2019, Stern and colleagues spotted a DFCI in 58.1% of competitive skiers. In the control group, only 26.7% demonstrated the irregularity. And such injuries are likely in other athletes who put consistent strain on their gastrocnemius muscles, Stern warned.

“This would apply to basketball and volleyball players,” he added. “It might also apply for weightlifters who are exposed to similar pretension states and eccentric loading of the gastrocnemius muscles as skiers during exercise.”

According to the research team, invasive procedures such as biopsies should be avoided in patients with DFCI, where possible. Follow-up MRI may be useful, however, in rare cases where the injury causes pain and other symptoms, the group concluded.

Read the full study published June 16 in Radiology.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview. 

Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.

Elucid's PlaqueIQ was trained to turn CCTA images into interactive 3D reports that help physicians visualize the presence of atherosclerosis.

Trimed Popup
Trimed Popup